Opinion|Videos|July 1, 2024
Duration of Therapy and Dosing Strategies in RCC
Author(s)Martin H. Voss, MD
An expert on non–clear cell renal cell carcinoma provides clinical insights on TKI dosing strategies and duration of therapy implications for IO-TKI combinations.
Advertisement
Episodes in this series
Video content above is prompted by the following question(s):
- In your experience, what is the optimal duration of treatment with lenvatinib in patients with advanced renal clear cell carcinoma?
- How do you monitor patients and make decisions around continuing or discontinuing treatment in clinical practice?
- When do you consider switching therapies versus dose reductions to maintain treatment duration?
Advertisement
Related to this article
Oncologists weigh second-line options after IO/TKI failure in metastatic ccRCC, highlighting tolerability, mechanism shifts, and belzutifan’s broader role.
The FDA has approved Omcazio, a capsule-based formulation of cabozantinib as a laurylsulfate salt, that demonstrated bioequivalence to the existing tablet.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Imlunestrant Plus Abemaciclib in ESR1-Mutated Breast Cancer
2
Data Increasingly Favor BCMA-Directed Therapy For Early-Relapse Myeloma
3
Sub-Q Amivantamab and Supportive Care Minimize Discontinuation in EGFR+ NSCLC
4
Daraxonrasib Combo Receives FDA Breakthrough Status in First-Line PDAC
5